NCT06012448: Dupilumab for chronic unexplained dermal rash

Study: University of Michigan investigation of dupilumab for chronic idiopathic dermal hypersensitivity reaction, with Regeneron collaboration. 1 2

Design and measurements: The reproduced registry text describes a single-group, open-label study, with 10 actual participants. Eligibility required clinical and biopsy evidence of unexplained rash lasting at least six weeks, with moderate-to-severe involvement. All participants were to receive dupilumab through week 24, with laboratory testing, examinations, and selected skin biopsies during approximately 28 weeks of participation. 1 2

What is established: The reproduction displays completed status, but its status and date fields are not sufficient to verify a final analyzed sample. No clinical-response or immunologic effect size was verified. A phase IV label does not establish approval or proven efficacy for this particular rash indication. 1 2

Sources

1. ClinicalTrials.gov — ClinicalTrials.gov — NCT06012448. Original study registration: sponsor, design, population, endpoints and dated history.Original study registration · Original record checked against the registry API. Checked 2026-10-10. Registration and current registry fields do not by themselves establish efficacy. Historical details in the article retain their stated date. Supplied note: ClinicalTrials.gov — NCT06012448. Original study registration: sponsor, design, population, endpoints and dated history.

2. Inspected CDEK reproduction of registry text. Readable registry-data reproduction, not an independent efficacy study — Inspected CDEK reproduction of registry text. Readable registry-data reproduction, not an independent efficacy study.Cited supporting source · Link and description preserved from supplied research. Checked in supplied research dated 2026-10-10. Source description comes from supplied research; underlying page was not independently re-read for this update.